Fred Alger Management’s Larimar Therapeutics LRMR Stock Holding History

Fred Alger Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$95.7K	Buy	+21,267	New	+$85K	﹤0.01%	443
2025 Q1	–	Sell	-737,553	Closed	-$2.85M	–	453
2024 Q4	$2.85M	Sell	737,553 -49,035	-6%	-$324K	0.01%	299
2024 Q3	$5.15M	Sell	786,588 -146,906	-16%	-$1.18M	0.03%	236
2024 Q2	$6.77M	Sell	933,494 -54,439	-6%	-$417K	0.03%	220
2024 Q1	$7.5M	Buy	987,933 +901,372	+1,041%	+$7.02M	0.04%	221
2023 Q4	$394K	Sell	86,561 -29,708	-26%	-$100K	﹤0.01%	406
2023 Q3	$459K	Buy	116,269 +21,331	+22%	+$80.7K	﹤0.01%	385
2023 Q2	$297K	Sell	94,938 -190,797	-67%	-$778K	﹤0.01%	420
2023 Q1	$1.29M	Buy	+285,735	New	+$1.49M	0.01%	372
2022 Q1	–	Sell	-175,870	Closed	-$1.9M	–	535
2021 Q4	$1.9M	Hold	175,870	–	–	﹤0.01%	360
2021 Q3	$2.03M	Buy	+175,870	New	+$2.11M	﹤0.01%	347
2015 Q2	–	Sell	-1,271	Closed	-$604K	–	521
2015 Q1	$604K	Buy	+1,271	New	+$603K	﹤0.01%	537

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fred Alger Management's LRMR Position: Q1 2026 in Review

Fred Alger Management opened a new position in Larimar Therapeutics (LRMR) in Q1 2026: 21,267 shares worth $95.7K. The stake represents ﹤0.01% of the portfolio and ranks #443 among its holdings. This is a return to the name: Fred Alger Management previously reported a position in LRMR as recently as Q4 2024.

Fred Alger Management first reported a position in LRMR in Q1 2015 and has held it in 12 quarters since. The position peaked at $7.5M in Q1 2024. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

Fred Alger Management held 21,267 shares of Larimar Therapeutics worth $95.7K as of Q1 2026.
Larimar Therapeutics was a new Fred Alger Management position in Q1 2026.
Larimar Therapeutics made up ﹤0.01% of Fred Alger Management's portfolio in Q1 2026, its #443 holding.
Fred Alger Management first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 12 quarters since.
Fred Alger Management's Larimar Therapeutics position peaked at $7.5M in Q1 2024.
162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.